Related Experiment Video
Updated: Jul 2, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy
Yonggui Wu1, Jing Dong, Liang Yuan
1Department of Nephrology, The First Affiliated Hospital, Anhui Medical University, Road Ji Xi, Hefei, Anhui 230022, PR China. wuyonggui@medmail.com.cn
Abstract:
Several works in the setting of early experimental diabetic nephropathy using anti-inflammatory drugs, such as mycophenolate mofetil (MMF), have shown that prevention of the development or amelioration of renal injury including proteinuria. The exact mechanisms by which anti-inflammatory drugs lower the albuminuria have no still to clarify well. In this study, diabetes was induced by injection of streptozotocin after uninephrectomy. Rats were randomly divided into three groups: control group, diabetic group and diabetic group treated with MMF. Elevated 24h urinary albumin excretion rate was markedly attenuated by MMF treatment. In diabetic rats receiving no treatment, there were increase in ED-1+ cells in the glomeruli, which were effectively suppressed by MMF treatment. The expression of nephrin and podocin protein was reduced in the glomeruli from diabetic rats, and MMF treatment significantly increased the expression of nephrin and podocin. The expression of IL-1, TNF-alpha and 3-NT protein in the glomeruli were significantly increased in diabetic rats, which were all significantly inhibited by MMF treatment. Our results show that MMF could decrease urinary albumin excretion, which mechanism may be at least partly correlated with upregulated expression of nephrin and podocin in the glomeruli of diabetic rat.
Insights
Mycophenolate mofetil (MMF) treatment reduced albuminuria in diabetic rats by upregulating nephrin and podocin expression. This anti-inflammatory drug suppressed glomerular inflammation and injury, offering a potential therapeutic mechanism for diabetic nephropathy.
Area of Science:
- Nephrology
- Pharmacology
- Experimental Medicine
Background:
- Diabetic nephropathy is a major complication of diabetes, characterized by renal injury and proteinuria.
- Anti-inflammatory drugs, including mycophenolate mofetil (MMF), show promise in ameliorating kidney damage, but mechanisms remain unclear.
- Understanding how MMF reduces albuminuria is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the therapeutic effects and underlying mechanisms of MMF in experimental diabetic nephropathy.
- To evaluate MMF's impact on urinary albumin excretion, glomerular inflammation, and key protein expression in diabetic rats.
Main Methods:
- Diabetes was induced in uninephrectomized rats using streptozotocin.
- Rats were divided into control, diabetic, and MMF-treated diabetic groups.
- Evaluated 24-hour urinary albumin excretion, glomerular ED-1+ cell infiltration, and expression of nephrin, podocin, IL-1, TNF-alpha, and 3-NT.
Main Results:
- MMF treatment significantly reduced 24-hour urinary albumin excretion in diabetic rats.
- MMF suppressed the increase in glomerular ED-1+ cells (indicating inflammation) observed in diabetic rats.
- MMF upregulated the expression of nephrin and podocin proteins, while inhibiting increased IL-1, TNF-alpha, and 3-NT protein levels.
Conclusions:
- MMF effectively attenuates renal injury and albuminuria in experimental diabetic nephropathy.
- The protective mechanism of MMF may involve upregulating nephrin and podocin expression in glomeruli.
- MMF's anti-inflammatory actions contribute to its renoprotective effects in diabetes.
Related Concept Videos
Diabetic Nephropathy
Nephrotic Syndrome I : Introduction
Diabetic Retinopathy
Nephrons
Acute Kidney Injury IV: Diagnostic Studies and Prevention
